FLGT (Fulgent Genetics, Inc. Common Stock) Stock | Pipeline, Insider Trades & Financials

Jul 9, 2026

Fulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026

Fulgent Genetics, Inc. announced it will release its second quarter 2026 financial results on July 30, 2026. The company will hold a conference call at 4:30 PM ET the same day to discuss these results with the investment community. This event highlights Fulgent's commitment to transparency and investor engagement.

Jun 1, 2026

Fulgent Presents Updated FID-007 Data at ASCO 2026

Fulgent presented updated data on FID-007 at the ASCO 2026 conference. The details of the data and its implications were not disclosed in the article. The presentation aimed to inform stakeholders about the progress of FID-007 in clinical settings.

May 21, 2026

▲ +5.9%on this news

Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting

Fulgent has announced the rapid oral full abstract publication for FID-007, which will be presented within the Head and Neck Cancer track session at the ASCO 2026 Annual Meeting. This event highlights the company's ongoing research efforts in oncology. Further details about the findings and implications of FID-007 are anticipated during the meeting.

Fulgent Reports First Quarter 2026 Financial Results

Fulgent Genetics reported its first quarter 2026 financial results, revealing a revenue of $71.1 million but a GAAP loss of $24.8 million. The company is optimistic about its laboratory services and therapeutic development pipeline, particularly with the upcoming presentation of Phase 2 data for FID-007 at the 2026 ASCO Annual Meeting. Despite the losses, Fulgent maintains its revenue guidance for the year and anticipates improvements in gross margins.

Apr 22, 2026

Fulgent Selected to Present Rapid Oral Abstract Within the Head and Neck Cancer Track Session at the 2026 ASCO Annual Meeting

Fulgent has been chosen to present a rapid oral abstract during the Head and Neck Cancer track at the 2026 ASCO Annual Meeting. This opportunity highlights the company's involvement in significant oncology discussions. The details of the abstract and its implications for the field will be revealed at the event.

Apr 17, 2026

Fulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026

Fulgent Genetics, Inc. will announce its first quarter 2026 financial results on May 1, 2026. The company will host a conference call at 8:30 AM ET to discuss the results and engage with the investment community. Fulgent is focused on transitioning from a diagnostic business to a fully integrated precision medicine company.

Apr 16, 2026

Fulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026

Fulgent Genetics is set to announce its financial results for the first quarter of 2026 on May 1, 2026. The announcement is part of the company's regular financial reporting schedule. Further details regarding the results will be provided at the time of the announcement.

Mar 18, 2026

Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx

Fulgent Genetics has completed the acquisition of Bako Diagnostics and StrataDx for approximately $56.9 million. This acquisition is expected to enhance Fulgent's laboratory services and therapeutic development capabilities. The company aims to transition into a fully integrated precision medicine entity, leveraging the expertise of the acquired laboratories.

Fulgent Reports Fourth Quarter and Full Year 2025 Financial Results

Fulgent Genetics reported its financial results for Q4 and full year 2025, highlighting growth in its laboratory services and advancements in its therapeutic pipeline. CEO Ming Hsieh expressed optimism about ongoing strategic investments and product innovation. However, CFO Paul Kim noted potential revenue impacts from a key customer internalizing testing work, despite a strong cash position and plans for growth in 2026.

Feb 12, 2026

Fulgent to Announce Fourth Quarter and Full Year 2025 Financial Results on Friday, February 27, 2026

Fulgent Genetics, Inc. will announce its fourth quarter and full year 2025 financial results on February 27, 2026. The announcement will be made before the market opens, followed by a conference call at 8:30 AM ET to discuss the results. The company is transitioning from diagnostics to a fully integrated precision medicine approach.

Dec 22, 2025

Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx Proposed acquisition will add new anatomic pathology services, proprietary PCR tests and a national client base EL MONTE, Calif.&#x2014

Fulgent Genetics, Inc. has announced a definitive agreement to acquire Bako Diagnostics and StrataDx for approximately $55.5 million. This acquisition aims to enhance Fulgent's laboratory services by adding anatomic pathology and dermatopathology services, as well as proprietary PCR tests. The deal is expected to close in the first half of 2026, pending regulatory approvals. With this acquisition, Fulgent seeks to strengthen its commercial reach and expand its capabilities in the diagnostics sector, particularly through advancements in AI and digital pathology.

Nov 7, 2025

▲ +18.2%on this news· ran to +30% by day 3

Fulgent Reports Third Quarter 2025 Financial Results • Revenue of $84.1 million, growing 17% year-over-year • Raising Full Year 2025 Revenue Guidance to $325.0 million • Raising Full Year 2025 EPS Gu

Fulgent Genetics reported a robust third quarter for 2025, achieving a revenue of $84.1 million, marking a 17% year-over-year increase. The company raised its full-year revenue guidance to $325 million and recorded a non-GAAP income of $4.5 million. Despite a GAAP loss of $6.6 million for the quarter, Fulgent emphasizes strong cash reserves of $787.7 million and expressed confidence in continued momentum in its laboratory services and therapeutic development business. Additionally, the company acknowledged ongoing efforts in clinical trials, particularly for cancer treatments.

Fulgent Shares Preliminary Data from Poster Presentation at ESMO 2025 Conference

Fulgent Genetics announced preliminary clinical data from its Phase 2 trial investigating FID-007 combined with cetuximab for treating recurrent or metastatic head and neck squamous cell carcinoma. The data, presented at the ESMO 2025 Conference, shows promising efficacy and safety profiles, with an overall objective response rate of 51%. Furthermore, the trial indicates a median progression-free survival significantly better than historical standards. The study reflects Fulgent's ambition to advance its therapeutic development capabilities.

Aug 1, 2025

▲ +7.9%on this news· ran to +20% by day 3

Fulgent Reports Second Quarter 2025 Financial Results • Core Revenue of $81.7 million grows 16% year-over-year • Raising Full Year 2025 Core Revenue Guidance to $320 million • GAAP gross profit of $3

Fulgent Genetics reported its financial results for the second quarter of 2025, demonstrating a 16% growth in core revenue year-over-year, amounting to $81.7 million. The company is raising its full-year core revenue guidance to $320 million, indicating strong momentum within its laboratory services business. Despite these positive aspects, Fulgent reported a GAAP loss of $19.0 million, reflecting underlying challenges. The company maintains a robust cash position of $777.5 million as it navigates forward, showing commitment to growth in its therapeutic development sector.

Fulgent Reports First Quarter 2025 Financial Results • Core Revenue of $73.5 million grows 16% year-over-year • Reiterating Full Year 2025 Core Revenue Guidance of $310 million • Non-GAAP income of $

Fulgent Genetics, Inc. reported its financial results for the first quarter of 2025, achieving a core revenue of $73.5 million, which reflects a 16% increase year-over-year. The company reiterated its guidance for the full year, expecting a core revenue of approximately $310 million. However, it faced a GAAP loss of $11.5 million in the same quarter, highlighting continued financial pressures. Despite these losses, Fulgent maintains a significant cash position of $814.6 million and is optimistic about its growth trajectory in the laboratory services and therapeutic development sectors.

Feb 28, 2025

Fulgent Reports Fourth Quarter and Full Year 2024 Financial Results • Full Year Total Revenue of $283.5 million • Full Year Core Revenue grows 7% year-over-year to $281.2 million • Ended 2024 with $8

Fulgent Genetics, Inc. reported its fourth quarter and full year financial results for 2024, showcasing a total revenue of $283.5 million. Core revenue grew by 7% year-over-year, while the company ended 2024 with substantial cash reserves totaling $828.6 million. However, the financial results also showed a significant GAAP loss of $42.7 million for the year. Looking ahead, Fulgent expects core revenue to reach approximately $310 million in 2025 despite predicting continued GAAP losses.

Fulgent Reports Third Quarter 2024 Financial Results • Total Revenue of $71.7 million • Core Revenue grows 9% year-over-year to $71.7 million • Reiterates Full Year 2024 Core Revenue Guidance of $280

Fulgent Genetics, Inc. reported third-quarter financial results for 2024, showcasing total revenues of $71.7 million, a year-over-year increase in core revenue of 9%. The company has reiterated its guidance for full-year core revenue at approximately $280 million and has improved its earnings per share forecast for 2024. Although the company experienced a GAAP loss of $14.6 million, it reported a non-GAAP income of $9.4 million. Additionally, Fulgent highlights promising early results from its Phase 2 clinical trial of FID-007 in head and neck cancer.

Fulgent Reports Second Quarter 2024 Financial Results • Total Revenue of $71.0 million • Core Revenue grows 5% year-over-year to $70.2 million • Reiterates Full Year 2024 Core Revenue Guidance of $28

Fulgent Genetics, Inc. reported its financial results for the second quarter of 2024, revealing a total revenue of $71.0 million and a core revenue growth of 5% year-over-year to $70.2 million. Although the company posted a GAAP loss of $8.7 million, it improved its non-GAAP income guidance for the year, projecting total core revenue of approximately $280 million. Fulgent continues to maintain a solid cash position of $837.9 million while advancing its therapeutic development, particularly in precision diagnostics and cancer therapies. The company's outlook remains cautiously optimistic despite reported operational losses.

May 3, 2024

Fulgent Reports First Quarter 2024 Financial Results • Total Revenue of $64.5 million • Core Revenue grows 1% year-over-year to $63.2 million • Reiterates Full Year 2024 Core Revenue Guidance of $280

Fulgent Genetics, Inc. reported its financial results for the first quarter of 2024, revealing total revenue of $64.5 million, with core revenue growing 1% year-over-year to $63.2 million. Despite this revenue growth, the company experienced a GAAP loss of $13.5 million. The company reiterated its full-year guidance, anticipating core revenue of approximately $280 million while highlighting its strategic initiatives in therapeutic development. Fulgent's cash position remains strong at $846.2 million as of the end of March 2024.

Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results • Full Year 2023 Total Revenue of $289.2 million; Q4 2023 Total Revenue of $70.5 million • Full Year 2023 Core Revenue grows 44% year-over

Fulgent Genetics reported its financial results for Q4 and full year 2023, showing strong core revenue growth of 44%, totaling $289.2 million in revenue. Despite a GAAP loss of $167.8 million for the year, the company's cash position remains robust at $847.7 million. Fulgent is making notable advancements in its therapeutic development pipeline, including plans for IND application filings. The outlook for 2024 includes projected core revenue of approximately $280 million.

Fulgent Reports Third Quarter 2023 Financial Results • Core Revenue of $66 million represents Growth of 17% Year-over-Year • Additional Reimbursement from COVID-19 Test Sales yields Revenue of $19 million,

Fulgent Genetics, Inc. has reported its financial results for Q3 2023, indicating a total revenue of $85 million and core revenue growth of 17% compared to the prior year. Despite GAAP and non-GAAP losses, the company maintains a strong cash position of $851 million as of September 30, 2023, and has reiterated its full-year core revenue guidance. Additionally, Fulgent plans to advance its therapeutic development program with the initiation of Phase 2 studies for FID-007 in early 2024.

Aug 4, 2023

Fulgent Reports Second Quarter 2023 Financial Results • Total Revenue of $68 million • Record Core Revenue of $67 million, growth of 48% year-over-year • Raises Full Year 2023 Core Revenue Guidance t

Fulgent Genetics reported its second quarter 2023 financial results, revealing a total revenue of $68 million and a core revenue growth of 48% year-over-year, reaching a record $67 million. The company raised its full year core revenue guidance to $260 million while also narrowing its expected loss. However, Fulgent incurred a GAAP loss of $11.2 million and a non-GAAP loss of $2.4 million. The company remains optimistic about its core business and therapeutic development, expressing plans for the initiation of Phase 2 studies by the end of 2023.

Fulgent Reports First Quarter 2023 Financial Results • Total Revenue of $66.2 million • Record Core Revenue of $62.7 million, growth of 150% year-over-year • Raises Full Year 2023 Core Revenue Guidan

Fulgent Genetics announced its financial results for the first quarter of 2023, reporting total revenue of $66.2 million and a record core revenue of $62.7 million, marking a significant growth of 150% year-over-year. The company has raised its core revenue guidance for the full year to $250 million, demonstrating confidence in its ongoing business operations. However, Fulgent also reported a GAAP loss of $15.3 million, highlighting some ongoing challenges despite strong revenue growth. The company plans to share data on its lead drug candidate, FID-007, at an upcoming oncology meeting.

Feb 28, 2023

Fulgent Reports Fourth Quarter and Full Year 2022 Financial Results • Full Year 2022 Total Revenue of $619.0 million; Q4 Total Revenue of $67.7 million • Full Year 2022 Core Revenue grows 95% year-over-year

Fulgent Genetics, Inc. reported its financial results for Q4 and full year 2022, demonstrating significant growth in core revenue which increased 95% year-over-year to $181.5 million. Despite a GAAP loss of $23.8 million in Q4, the overall total revenue for the full year reached $619.0 million, reflecting a strong core business momentum. The company plans for sustainable revenue generation moving forward, particularly in domains such as precision diagnostics and oncology. Fulgent also announced expectations for Q1 2023 revenue around $56.0 million, alongside a projected GAAP loss.

Jan 3, 2023

Fulgent Expands Board of Directors with Addition of Reggie Groves TEMPLE CITY, California &#x2013

Fulgent Genetics announced the appointment of Reggie Groves to its Board of Directors, effective January 3, 2023. Groves brings a wealth of experience from her previous roles in medical technology, including significant positions at Medtronic. Her expertise is expected to be invaluable as Fulgent aims to enhance its offerings in precision medicine, particularly following its recent acquisition of Fulgent Pharma. The addition of Groves aligns with the company's strategic focus on advancing comprehensive solutions across the cancer care continuum.

Fulgent Genetics Reports Third Quarter 2022 Financial Results • Revenue totals $105.7 million • Core Revenue grows 110% year-over-year to $56.0 million

Fulgent Genetics Reports Third Quarter 2022 Financial Results -Revenue totals $105.7 million -Core Revenue grows 110% year-over-year to $56.0 million TEMPLE CITY, CA, November 7, 2022 Fulgent Genetics, Inc. (NASDAQ: FLGT) ( Fulgent Genetics , Fulgent , or the Company ), a tech

Aug 4, 2022

Fulgent Genetics Reports Second Quarter 2022 Financial Results • Revenue totals $125.3 million • Core Revenue grows 102% year-over-year to $45.3 million • Raises full year core revenue outlook to $18

Fulgent Genetics Reports Second Quarter 2022 Financial Results -Revenue totals $125.3 million -Core Revenue grows 102% year-over-year to $45.3 million -Raises full year core revenue outlook to $185 million from previously announced $180 million TEMPLE CITY, CA, August 4, 2022

May 3, 2022

Fulgent Genetics Reports First Quarter 2022 Financial Results • Revenue totals $320.3 million • Core Revenue excluding COVID-19 NGS testing grows 59% year-over-year to $25.1 million • Raises full yea

Fulgent Genetics Reports First Quarter 2022 Financial Results -Revenue totals $320.3 million -Core Revenue excluding COVID-19 NGS testing grows 59% year-over-year to $25.1 million -Raises full year revenue outlook to $660 million from previously announced $600 million -Raises

Apr 18, 2022

Fulgent Genetics Agrees to Acquire Inform Diagnostics and Provides Preliminary First Quarter Revenue Results Proposed acquisition will add diagnostic offerings, including hematopathology and anatomic pathology, while als

Fulgent Genetics Agrees to Acquire Inform Diagnostics and Provides Preliminary First Quarter Revenue Results Proposed acquisition will add diagnostic offerings, including hematopathology and anatomic pathology, while also providing a highly complementary nationwide commercial in

Feb 23, 2022

Fulgent Genetics Reports Fourth Quarter and Full Year 2021 Financial Results Full Year 2021 Total Revenue grows 135% year-over-year to $992.6 million; Q4 Revenue totals $251.7 million Full Year 2021 Core Revenue grows 23

Fulgent Genetics Reports Fourth Quarter and Full Year 2021 Financial Results TEMPLE CITY, CA, February 23, 2022 -Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent Genetics", "Fulgent", or the "Company"), a technology-based genetic testing company focused on transforming patient ca

Nov 9, 2021

Fulgent Genetics Reports Third Quarter Financial Results Revenue grows 124% year-over-year to $227.9 million Core Revenue grows 292% year-over-year to $40.1 million Raises Full Year Revenue guidance to $930 million from

Fulgent Genetics Reports Third Quarter Financial Results TEMPLE CITY, CA, November 9, 2021 -Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent Genetics" or the "company"), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and ra

Aug 9, 2021

Fulgent Genetics Reports Second Quarter Financial Results • Revenue grows 790% year over year to $153.6 million • Core Revenue grows 296% year over year to $25.7 million • Announces acquisition of CS

Fulgent Genetics Reports Second Quarter Financial Results TEMPLE CITY, CA, August 9, 2021 -Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "company"), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare disease

May 6, 2021

Fulgent Genetics Reports Record First Quarter Financial Results First Quarter 2021 Results : Record Revenue of $359.4 million, growing more than 4,500% year-over-year Record Billable tests delivered approximately 3.8 mil

Fulgent Genetics Reports Record First Quarter Financial Results First Quarter 2021 Results: TEMPLE CITY, CA, May 6, 2021 -Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "company"), a technology company providing large-scale COVID-19 testing services and comprehensive t

Mar 4, 2021

Fulgent Genetics Reports Record Fourth Quarter and Full Year 2020 Financial Results Fourth Quarter 2020 Results : Record Revenue of $295.0 million, growing more than 3,400% year-over-year Record Billable tests delivered

Fulgent Genetics Reports Record Fourth Quarter and Full Year 2020 Financial Results Fourth Quarter 2020 Results: TEMPLE CITY, CA, March 4, 2021 -Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "company"), a technology company providing large-scale COVID-19 testing servi

Nov 23, 2020

Fulgent Genetics Announces Increase to Full Year 2020 Guidance to $300 million

Fulgent Genetics Announces Increase to Full Year 2020 Guidance to $300 million TEMPLE CITY, California - November 23, 2020 - Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent Genetics" or the "company"), a technology company providing comprehensive testing solutions through its sc

Nov 9, 2020

Fulgent Genetics Reports Record Third Quarter 2020 Financial Results and Raises Full Year 2020 Revenue Guidance by $100 Million Third Quarter 2020 Results : • Record Revenue of $101.7 million, growing more than 88

Fulgent Genetics Reports Record Third Quarter 2020 Financial Results and Raises Full Year 2020 Revenue Guidance by $100 Million Third Quarter 2020 Results: TEMPLE CITY, CA, November 9, 2020 -Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "company"), a technology compan

Aug 4, 2020

Fulgent Genetics Reports Record Second Quarter 2020 Financial Results Second Quarter 2020 Results : • Record Revenue of $17.3 million, growing 105% year-over-year • Record Billable tests delivered total 180

Fulgent Genetics Reports Record Second Quarter 2020 Financial Results Second Quarter 2020 Results: TEMPLE CITY, CA, August 4, 2020 -Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "company"), a technology company providing comprehensive testing solutions through its sca

May 4, 2020

Fulgent Genetics Reports First Quarter 2020 Financial Results First Quarter 2020 Results : • Revenue totals $7.8 million, growing 44% year over year • Billable tests delivered total 13,163, growing 75% year

Fulgent Genetics Reports First Quarter 2020 Financial Results First Quarter 2020 Results: TEMPLE CITY, CA, May 4, 2020 -Fulgent Genetics (NASDAQ: FLGT) ("Fulgent Genetics" or the "company"), a provider of comprehensive genetic testing and Next Generation Sequencing ("NGS") solu

Mar 10, 2020

Fulgent Genetics Reports Fourth Quarter and Full Year 2019 Financial Results Fourth Quarter 2019 Results : • Revenue totals $8.4 million, growing 48% year over year • Billable tests delivered total 13,977,

Fulgent Genetics Reports Fourth Quarter and Full Year 2019 Financial Results Fourth Quarter 2019 Results: Full Year 2019 Results: TEMPLE CITY, CA, March 10, 2020 -Fulgent Genetics (NASDAQ: FLGT) ("Fulgent Genetics" or the "company"), a provider of comprehensive genetic testing

Nov 13, 2019

Fulgent Genetics Announces Proposed Public Offering of Common Stock

Fulgent Genetics Announces Proposed Public Offering of Common Stock TEMPLE CITY, Calif., November 13, 2019 -Fulgent Genetics (NASDAQ: FLGT) ("Fulgent Genetics" or the "Company"), a provider of comprehensive genetic testing and Next Generation Sequencing (NGS) solutions, today an

Nov 4, 2019

Fulgent Genetics Reports Third Quarter 2019 Financial Results Third Quarter 2019 Results : • Record billable tests of 20,697, growing 272% year over year • Record revenue of $10.3 million, growing 84% year

Fulgent Genetics Reports Third Quarter 2019 Financial Results Third Quarter 2019 Results: TEMPLE CITY, CA, November 4, 2019 -Fulgent Genetics (NASDAQ: FLGT) ("Fulgent Genetics" or the "company"), a provider of comprehensive genetic testing and Next Generation Sequencing (NGS) s

Aug 5, 2019

Fulgent Genetics Reports Second Quarter 2019 Financial Results Second Quarter 2019 Results : • Record billable tests of 16,369, growing 187% year over year • Record revenue of $8.4 million, growing 56% year

Fulgent Genetics Reports Second Quarter 2019 Financial Results Second Quarter 2019 Results: TEMPLE CITY, CA, August 5, 2019 -Fulgent Genetics (NASDAQ: FLGT) ("Fulgent Genetics" or the "company") today announced financial results for its second quarter ended June 30, 2019. Seco

Aug 5, 2019

Fulgent Genetics Names Linda Marsh to Board of Directors

Fulgent Genetics Names Linda Marsh to Board of Directors TEMPLE CITY, California -August 5, 2019 - Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent Genetics", "Fulgent" or the "company") today announced the addition of Linda Marsh, Senior Executive Vice President of AHMC Healthca

May 7, 2019

Fulgent Genetics Reports First Quarter 2019 Financial Results First Quarter 2019 Results : • Revenue totals $5.4 million, growing 15% year over year • Billable tests delivered total 7,530, growing 63% year

Fulgent Genetics Reports First Quarter 2019 Financial Results First Quarter 2019 Results: TEMPLE CITY, CA, May 7, 2019 -Fulgent Genetics (NASDAQ: FLGT) ("Fulgent Genetics" or the "company") today announced financial results for its first quarter ended March 31, 2019. First qua

Feb 28, 2019

Fulgent Genetics Reports Fourth Quarter and Full Year 2018 Financial Results Fourth Quarter 2018 Results : • Revenue totals $5.7 million, growing 33% year over year • Billable tests delivered total 6,408, g

Fulgent Genetics Reports Fourth Quarter and Full Year 2018 Financial Results Fourth Quarter 2018 Results: Full Year 2018 Results: TEMPLE CITY, CA, February 28, 2019 -Fulgent Genetics (NASDAQ: FLGT) ("Fulgent Genetics" or the "company") today announced financial results for its

Nov 6, 2018

Fulgent Genetics Reports Third Quarter 2018 Financial Results Third Quarter 2018 Results : • Revenue totals $5.6 million, growing 25% year over year and 4% sequentially • Billable tests delivered total 5,56

Fulgent Genetics Reports Third Quarter 2018 Financial Results Third Quarter 2018 Results: TEMPLE CITY, CA, November 6, 2018 -Fulgent Genetics (NASDAQ: FLGT) ("Fulgent Genetics" or the "company") today announced financial results for its third quarter ended September 30, 2018.

Aug 6, 2018

Fulgent Genetics Reports Second Quarter 2018 Financial Results Second Quarter 2018 Results : • Revenue totals $5.4 million, growing 16% year over year and 16% sequentially • Billable tests delivered total 5

Fulgent Genetics Reports Second Quarter 2018 Financial Results Second Quarter 2018 Results: TEMPLE CITY, CA, August 6, 2018 -Fulgent Genetics (NASDAQ: FLGT) ("Fulgent Genetics" or the "company") today announced financial results for its second quarter ended June 30, 2018. Seco

May 7, 2018

Fulgent Genetics Reports First Quarter 2018 Financial Results First Quarter 2018 Results : • Revenue of $4.7 million, up 9% sequentially • Billable tests delivered grew 10% sequentially to 4,621 • GA

Fulgent Genetics Reports First Quarter 2018 Financial Results First Quarter 2018 Results: TEMPLE CITY, CA, May 7, 2018 -Fulgent Genetics (NASDAQ: FLGT) ("Fulgent Genetics" or the "company") today announced financial results for its first quarter ended March 31, 2018. First qua

Feb 28, 2018

Fulgent Genetics Reports Fourth Quarter and Full Year 2017 Financial Results Fourth Quarter of 2017 Results : • Revenue of $4.3 million • GAAP loss of $1.8 million, or $0.10 per share • Non-GAAP loss

Fulgent Genetics Reports Fourth Quarter and Full Year 2017 Financial Results Fourth Quarter of 2017 Results: Full Year 2017 Results: TEMPLE CITY, CA, February 28, 2018 -Fulgent Genetics (NASDAQ: FLGT) ("Fulgent Genetics" or the "company") today announced financial results for

Nov 6, 2017

Fulgent Genetics Reports Third Quarter 2017 Financial Results • Revenue of $4.5 Million • GAAP Loss of $1.1 million, or $0.06 per Share • Non-GAAP loss of $442,000, or $0.02 per Share • Adjust

Fulgent Genetics Reports Third Quarter 2017 Financial Results TEMPLE CITY, CA, November 6, 2017 -Fulgent Genetics (NASDAQ: FLGT) ("Fulgent" or the "company") today announced financial results for its third quarter ended September 30, 2017. Third quarter revenue was $4.5 million

Aug 7, 2017

Fulgent Genetics Reports Second Quarter 2017 Financial Results • Revenue grows 17% year over year to $4.6 Million • GAAP Loss of $25,000, or $0.00 per Share • Non-GAAP Income of $284,000, or $0.02 pe

Fulgent Genetics Reports Second Quarter 2017 Financial Results TEMPLE CITY, CA, August, 7, 2017 -Fulgent Genetics (NASDAQ: FLGT) ("Fulgent" or the "company") today announced financial results for its second quarter ended June 30, 2017. Second quarter revenue was $4.6 million, a

May 8, 2017

Fulgent Genetics Reports First Quarter 2017 Financial Results • Revenue grows 54% year over year to $5.3 Million • GAAP Income of $0.2 Million, or $0.01 per Share • Non-GAAP Income of $0.6 Million, o

Fulgent Genetics Reports First Quarter 2017 Financial Results TEMPLE CITY, CA, May, 8, 2017 -Fulgent Genetics (NASDAQ: FLGT) ("Fulgent" or the "company") today announced financial results for its first quarter ended March 31, 2017. First quarter revenue was $5.3 million, an inc

Feb 27, 2017

Fulgent Genetics Reports Fourth Quarter and Full Year 2016 Financial Results Fourth Quarter Revenue doubles year over year to $5.9 Million and reaches $18.3 Million for the Full Year of 2016 Fourth Quarter 2016 GAAP Inco

Fulgent Genetics Reports Fourth Quarter and Full Year 2016 Financial Results TEMPLE CITY, CA, February, 27, 2017 Fulgent Genetics (NASDAQ: FLGT) ( Fulgent or the company ) today announced financial results for the fourth quarter and full year ended December 31, 2016. Fourth qu

Nov 3, 2016